Free Webinars, Masterclasses and Podcasts

Watch our on-demand webinars

Pearce IP publishes its masterclasses, webinars and podcasts addressing various aspects of patent and trade mark law and practice in Australia free of charge.

Masterclass: an in-depth analysis of a subject of interest

PiPCast™: a 10 minute weekly sound bite on a “hot topic” in IP law

Other Podcasts: Pearce IP rehosts podcasts (of varying length) featuring its team members on varying subject matter.”

Search our webinars

Featured Image	Details

BioBlast®

Sanofi Secures Continued PBS Listing of Dupixent®

Dec 14, 2024

The Australian Government has reached an agreement with Sanofi and Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) to ensure Dupixent® (dupilumab) remains listed on the Pharmaceuticals Benefits Scheme (PBS) for eczema treatment, as it has been since 2021

Roche’s Vabysmo® (Faricimab) PFS Approved in EU

Dec 13, 2024

On 13 December 2024, Roche announced that the European Medicines Agency (EMA) has approved Vabysmo® (faricimab) pre-filled syringe (PFS) (6mg) for treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular oedema (DME) and macular oedema following retinal vein occlusion (RVO).

EMA Adopts Positive Opinion for Novo Nordisk’s Ozempic®

Dec 12, 2024

On 12 December 2024, Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the…

See Our BioBlast®

Blog

Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act

Dec 20, 2024

On 19 September 2024, the Federal Court of Australia delivered judgment ordering Medtronic Australasia Pty Ltd (Medtronic) to pay $22 million in penalties following proceedings bought by the Department of Health in August 2021…

Salt in the Wound: Federal Court Dissolves Novartis’ Patent Claims and Takes Aim at Hypothetical Tasks

Dec 17, 2024

On 13 November 2024, Justice Yates of the Federal Court of Australia delivered his decision in the dispute between Novartis AG and Novartis Pharmaceuticals Australia Pty Limited (together, Novartis) and Pharmacor Pty Limited (Pharmacor) regarding patent AU2003206738 entitled “Pharmaceutical compositions comprising valsartan and NEP inhibitors” (the Patent).

Pearce IP BioBlast® for the week ending 13 December 2024

Dec 16, 2024

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 December 2024 are set out below:

See Our blog

Awards

Pearce IP Firm and Leaders Recognised in Chambers Asia-Pacific and Global 2025 Rankings

Dec 13, 2024

We are delighted to announce that Pearce IP has been ranked for the second time in the prestigious Chambers Asia-Pacific and Global 2025 rankings for Intellectual Property (Australia). This recognition highlights our ongoing commitment to providing world-class intellectual property services, particularly in the pharmaceutical, biopharmaceutical, and life sciences sectors.

Pearce IP Founder Naomi Pearce is the 2024 Lawyers Weekly Women in Law “Executive of the Year”

Nov 19, 2024

We are delighted to announce that Pearce IP’s Founder & CEO, Naomi Pearce, was named Executive of the Year at the 2024 Lawyers Weekly Women in Law Awards. The Women in Law Awards recognise “the influence of exceptional women across the Australian legal...

Pearce IP Earns Double Recognition in Australasian Lawyer’s 2024 Elite Women

Nov 5, 2024

Pearce IP has earned double recognition in the fourth annual Australasian Lawyer 2024 "Elite Women" list, with 2 of its Executives recognised amongst the top 50 female leading the legal industry in Australia. Pearce IP's Founder and CEO Executive Lawyer, Patent...

See Our Awards